Clinical trials located in

Gütersloh

Gütersloh city is located in Germany. Currently, 6 clinical trials are being conducted in this city.

Gütersloh, located in North Rhine-Westphalia, Germany, is known for its lush green spaces and historical charm. The city is home to the Miele Company, a leading global manufacturer of high-end domestic appliances and commercial equipment, founded there in 1899. Gütersloh boasts the Stadtpark und Botanischer Garten, a beautifully maintained park and botanical garden, offering a serene escape with its diverse plant species and themed gardens. The city’s Water Tower, an iconic structure, provides panoramic views of the surrounding area. Gütersloh’s rich cultural scene is highlighted by its modern theater, which hosts a variety of performances throughout the year.

  • CT-EU-00057161

    Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Study of Early Breast Cancer Using Camizestrant or Hormone Therapy for Patients at Risk of Recurrence After At Least 2 Years of Standard Therapy

    The clinical trial focuses on patients with early-stage ER+/HER2- breast cancer, meaning the cancer is hormone-receptor-positive (ER+) and does not have an excess of the HER2 protein (HER2-). Participants must have an intermediate or high risk of disease recurrence and must have completed definitive locoregional therapy (such as surgery or radiotherapy) and at least 2 years but not more than 5 years of standard hormone therapy.

    The aim of the study is to assess the efficacy and safety of the drug Camizestrant (AZD9833) compared to standard hormone therapy, which may include aromatase inhibitors (e.g., letrozole, anastrozole, exemestane) or tamoxifen.

    Key measures will include the time to the recurrence of invasive breast cancer, invasive disease-free survival, distant relapse-free survival, overall survival, and the safety of the therapies used.

    Both women and men over 18 years old who meet specific criteria can participate in the study. Therapeutic effects and potential side effects will be monitored during the treatment. Patients will be observed for 10 years from the time of randomization into one of the study groups.

    • camizestrant
    • Anastrozole
    • Letrozole
    • Exemestane
    • tamoxifen
  • Study on durvalumab with oleclumab or monalizumab for lung cancer

    This is a study about two new treatments for a type of lung cancer called Non-small Cell Lung Cancer. This study is for adults with Stage III unresectable non-small cell lung cancer who’ve already had chemoradiation. It’s testing the effects of durvalumab combined with either oleclumab or monalizumab. The treatments are given through IV on a 28-day cycle for up to 12 months. The main goal is to see if these drug combinations can stop cancer from progressing and help patients live longer.

    • Oleclumab
    • Monalizumab
    • Durvalumab
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Germany:

.